Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trebananib Phase 1 in Japanese Patients
NCT02525536Phase 1Completed
- Sponsor
- Takeda
- Start
- Jun 2009
- Primary completion
- May 2014
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
01
Overview
Phase 1, open-label trial of trebananib in solid tumor (advanced stage) (3 arms), sponsored by Takeda. Primary endpoints: Dose Limiting Toxicity, Adverse Events and 11 more. Started Jun 2009; status: completed.
02
Drugs
trebananib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02525536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525536.